When did Valeant first talk about Philidor?

Valeant Pharmaceuticals (VRX) has drawn a lot of controversy over its ties to the specialty pharmacy Philidor.  An October 21, 2015 report by Citron Research was provocatively titled: “Valeant: Could this be the Pharmaceutical Enron?”. Making note of the report’s impact on Valeant securities, a Bloomberg news article remarked:

The company’s bonds erased more than a billion dollars in market value after the Citron report was published.

Read More